In an effort to combat such an alarmingly high mortality rate, various treatment therapies such as low tidal volume ventilation strategies, corticosteroid therapy, and use of nitric oxide (NO) have been attempted in the management of patients with ARDS.

We performed several subgroup and sensitivity analyses to assess the effects of INO in adults and children and on various clinical and physiological outcomes. We presented pooled estimates of the effects of interventions as risk ratios (RRs) with 95% confidence intervals (CIs).

This article delves into the role nitric oxide plays in the treatment of ARDS, its mechanisms, benefits, potential risks, and practical considerations for patients and healthcare providers.

ARDS isn't a single disease, but rather a collection of dozens of different diseases – anything which causes acute, diffuse parenchymal lung failure. In this way, ARDS is similar to “acute kidney injury.”

Apr 3, 2015 · Nitric oxide (NO) is a gas that functions as a cell signaling molecule. Within the lungs, NO stimulates increases in cellular cyclic GMP (cGMP) in vascular smooth muscle, leading to vasodilation.

To date, there have been several systematic reviews with meta-analysis that have shown no reduction in mortality with the use of inhaled nitric oxide (iNO) in patients with acute respiratory distress syndrome (ARDS).

Jun 27, 2016 · Objectives: The primary objective was to examine the effects of administration of inhaled nitric oxide on mortality in adults and children with ARDS. Secondary objectives were to examine secondary outcomes such as pulmonary bleeding events, duration of mechanical ventilation, length of stay, etc.

This pilot randomized controlled clinical trial of patients with ARDS was implemented to study the impact of inhaled nitric oxide (inhNO) on lung function, morbidity, and mortality.

Apr 24, 2023 · Overall, iNO seems a promising agent as it could improve the ventilation/perfusion mismatch, gas exchange impairment, and right ventricular failure, which are reported in ARDS. In addition, iNO may act as a viricidal agent and prevent lung hyperinflammation and thrombosis of the pulmonary vasculature in the specific setting of COVID-19 ARDS.

Oct 3, 2022 · In critically ill COVID-19 patients with moderate-to-severe ARDS, iNO rescue therapy is associated with improved oxygenation parameters but no mortality benefits. Moreover, iNO use is associated with higher odds of AKI, pneumonia, longer LOS, and fewer VFDs.